Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
received dose one and two and then came back late for RabAvert dose three; Case reference number US-BN-2026-000747 is a spontaneous case initially received from a pharmacist via Bavarian Nordic (reference number: CASE-2026-000808) on 11-May-2026 and concerns a 45-years-old male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient received first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at an unknown dose, site or route of administration for post-exposure prophylaxis. On an unspecified date, the patient received first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at an unknown dose, site or route of administration for post-exposure prophylaxis. The patient came back late for third dose of RabAvert (explicitly coded as inappropriate schedule of vaccine administered'). The patient was immunocompetent as post-exposure. At the time of initial report, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. No further information was provided.; Reporter's Comments: A 45-years-old male patient came back late for third dose of RabAvert which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. Causality is not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 45-years-old male patient came back late for third dose of RabAvert which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. Causality is not related to suspect product but to human factor. The case is non-serious.
Comments: None